Novocure Limited reported that Medicare billing privileges for its U.S. subsidiary were temporarily revoked and then fully restored. CMS had revoked billing for the company’s products retroactive to December 17, 2025 due to an administrative issue with a triannual re-validation process, not a substantive qualification failure.
On February 24, 2026, CMS rescinded the revocation and reinstated Medicare billing privileges retroactive to December 17, 2025. Novocure states it continued serving existing and new patients throughout this period and believes there will ultimately be no impact on its ability to recognize revenue for those services.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.